Joana holds a BSc in Biology, a MSc in Evolutionary and Developmental Biology and a PhD in Biomedical Sciences from Universidade de Lisboa, Portugal. Her work has been focused on the impact of non-canonical Wnt signaling in the collective behavior of endothelial cells — cells that made up the lining of blood vessels — found in the umbilical cord of newborns.
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to a combination treatment of IO Biotech’s ... Read more
The European Commission has approved Opdivo (nivolumab) as a second-line treatment for adults with advanced inoperable, recurrent, or metastatic esophageal squamous ... Read more
First-line treatment with a combination of Keytruda (pembrolizumab) plus chemotherapy significantly prolongs survival, and extends life without disease progression, in people ... Read more
The European Commission has approved the combination of Tecentriq (atezolizumab) and Avastin (bevacizumab) as a first-line treatment for adults with advanced ... Read more
When given as a first-line therapy, Libtayo (cemiplimab) prolonged the survival of patients with advanced non-small cell lung cancer (NSCLC), compared ... Read more
Adding Keytruda (pembrolizumab) to standard first-line chemotherapy significantly extends the survival of people with locally advanced or metastatic esophageal and gastroesophageal ... Read more
The U.S. Food and Drug Administration (FDA) has designated toripalimab (JS001) a breakthrough therapy as a potential treatment of nasopharyngeal carcinoma (NPC), one of the ... Read more
